Show simple item record

dc.contributor.authorGovindarajan, Baskaran
dc.contributor.authorWilloughby, Laura
dc.contributor.authorBand, Hamid
dc.contributor.authorCuratolo, Adam S
dc.contributor.authorVeledar, Emir
dc.contributor.authorChen, Suephy
dc.contributor.authorBonner, Michael Y.
dc.contributor.authorAbel, Martin-Garrido
dc.contributor.authorMoses, Marsha
dc.contributor.authorArbiser, Jack L
dc.date.accessioned2013-04-10T15:02:01Z
dc.date.issued2012
dc.identifier.citationGovindarajan, Baskaran, Laura Willoughby, Hamid Band, Adam S Curatolo, Emir Veledar, Suephy Chen, Michael Y Bonner, Martin-Garrido Abel, Marsha A Moses, and Jack L Arbiser. 2012. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vascular Cell 4:11.en_US
dc.identifier.issn2045-824Xen_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10522858
dc.description.abstractTuberous sclerosis (TS) is a common autosomal-dominant disorder characterized by tumors of the skin, lung, brain, and kidneys. Monotherapy with rapamycin however resulted in partial regression of tumors, implying the involvement of additional pathways. We have previously implicated platelet-derived growth factor-BB in TS-related tumorigenesis, thus providing a rationale for a combination of mTOR/PDGF blockade using rapamycin and imatinib. Here, we test this combination using a well-established preclinical model of cutaneous tumorigenesis in TS, tsc2ang1 cells derived from a skin tumor from a mouse heterozygous for tsc2. Treatment of tsc2ang1 cells with a combination of rapamycin and imatinib led to an inhibition of proliferation compared with either vehicle treatment or treatment with rapamycin or imatinib monotherapy. Combination therapy also led to a decrease in Akt activation. Potent in vivo activity in animal experiments by combination therapy was noted, without toxicity to the animals. Our findings provide a rationale for the combined use of rapamycin and imatinib, both FDA approved drugs, for the treatment of TS.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi:10.1186/2045-824X-4-11en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464934/pdf/en_US
dash.licenseLAA
dc.titleCooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasiaen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalVascular Cellen_US
dash.depositing.authorMoses, Marsha
dc.date.available2013-04-10T15:02:01Z
dc.identifier.doi10.1186/2045-824X-4-11*
dash.contributor.affiliatedMoses, Marsha


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record